Comparative Pharmacology
Head-to-head clinical analysis: MOXAM versus ZAGAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXAM versus ZAGAM.
MOXAM vs ZAGAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
400 mg orally every 24 hours for 7-14 days.
600 mg intravenously once daily or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
10-12 hours; prolonged in renal impairment
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Renal: 60-80% unchanged; biliary/fecal: 10-20%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic